Acer Therapeutics Inc (ACER)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Christopher Schelling
Employees:
40
ONE GATEWAY CENTER (300 WASHINGTON ST.), SUITE 356, NEWTON, MA, 02458
(844) 902-6100
-
Formally known as:
- Opexa Therapeutics, Inc.
Date | Ratio |
---|---|
2004-04-14 | 1:50 |
2006-06-19 | 1:1 |
2012-12-17 | 1:4 |
2015-09-29 | 1:8 |
2017-09-21 | 96:1000 |
Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|